Neoadjuvant therapy of Toripalimab plus Axitinib for Von Hipple-Lindau disease associated clear cell renal cell carcinoma: a single-arm, single-center, prospective study
Latest Information Update: 01 Dec 2020
At a glance
- Drugs Toripalimab (Primary) ; Axitinib
- Indications Renal cell carcinoma; Von Hippel-Lindau disease
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2020 New trial record